15 completed, 4 terminated, 2 recruiting, 2 unknown. 26 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 15, Terminated 4, Recruiting 2, Unknown 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Hepatitis, Alcoholic: new trials by email Literature Review of Hepatitis, Alcoholic trials Research Report on Hepatitis, Alcoholic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A-TANGO Phase 2 Study Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis | Phase 2 | Recruiting | Yaqrit Ltd | 78 | 2026-06-29 | 2026-09-21 |
| A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) ADX-629 - Alcohol Hepatitis | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 4 | 2024-11-04 | 2026-06-03 |
| MRG-001 in Patients With Alcoholic Hepatitis MRG-001 - Alcoholic Hepatitis, Acute Alcoholic Hepatitis | Phase 2 | Not yet recruiting | MedRegen LLC | 32 | 2024-09-01 | 2024-03-13 |
| Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis Fecal Microbiota Transplantation, Placebo - Alcoholic Hepatitis | Phase 1 / Phase 2 | Unknown | Prasun Kumar Jalal | 50 | 2023-01-21 | 2025-01-23 |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study INT-787, Placebo - Alcohol Associated Hepatitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 67 | 2022-12-15 | 2026-05-05 |
| Faecal Microbiota Transplantation for Liver Cirrhosis Faecal microbiota transplantation, Placebo - Liver Cirrhosis | Phase 2 / Phase 3 | Recruiting | University of Aarhus | 220 | 2021-07-01 | 2025-01-24 |
| DUR-928 in Patients With Alcoholic Hepatitis DUR-928 (Moderate AH), DUR-928 (Severe AH) - Alcoholic Hepatitis | Phase 2 | Completed | Craig James McClain | 43 | 2021-06-01 | 2023-10-18 |
| A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC) - Alcoholic Hepatitis | Phase 2 | Completed | Durect | 307 | 2021-01-22 | 2024-09-05 |
| Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis Anakinra and Zinc, Prednisone, Placebos - Alcoholic Hepatitis | Phase 2 | Completed | Indiana University | 147 | 2020-07-10 | 2025-02-10 |
| Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis Vitamin C, Dextrose 5% in water - Alcoholic Hepatitis, Sepsis | Phase 2 | Completed | Virginia Commonwealth University | 20 | 2019-04-16 | 2023-08-28 |
| IL-1 Signal Inhibition in Alcoholic Hepatitis Canakinumab 150mg/ml solution for injection, Placebo - Alcoholic Hepatitis | Phase 2 | Completed | Imperial College London | 55 | 2019-02-12 | 2025-03-11 |
| A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg - Alcoholic Hepatitis | Phase 2 | Completed | Durect | 19 | 2018-04-18 | 2024-09-24 |
| Pegfilgrastim in Patients With Alcoholic Hepatitis Standard of care + pegfiltrastim, Standard of care - Alcoholic Hepatitis | Phase 2 | Completed | Timothy Morgan, MD | 34 | 2017-01-21 | 2021-09-29 |
| Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) Selonsertib, Prednisolone, Placebo - Alcoholic Hepatitis (AH) | Phase 2 | Completed | Gilead Sciences | 104 | 2016-09-01 | 2019-02-06 |
| Use of F-652 in Patients With Alcoholic Hepatitis F-652 - Alcoholic Hepatitis | Phase 1 / Phase 2 | Completed | Mayo Clinic | 18 | 2016-02-01 | 2019-09-09 |
| A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis Mycophenolate mofetil, Prednisolone, Rilonacept - Alcoholic Hepatitis | Phase 2 | Completed | Southern California Institute for Research and Education | 4 | 2014-12-01 | 2025-06-12 |
| Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis IMM 124-E (Hyperimmune Bovine Colostrum), Placebo (High protein milk powder) - Hepatitis, Alcoholic | Phase 2 | Completed | Virginia Commonwealth University | 57 | 2014-12-01 | 2020-01-27 |
| Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Placebo, 10 mg Obeticholic Acid (OCA) - Alcoholic Hepatitis | Phase 2 | Terminated | Naga P. Chalasani | 19 | 2014-11-03 | 2020-01-28 |
| Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF IDN-6556, Placebo - Acute on Chronic Hepatic Failure, Acute Liver Failure | Phase 2 | Terminated | Conatus Pharmaceuticals Inc. | 23 | 2013-09-01 | 2016-04-11 |
| Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis Anakinra, Pentoxifylline, Zinc Sulfate - Acute Alcoholic Hepatitis | Phase 2 / Phase 3 | Completed | Mack Mitchell | 104 | 2013-09-01 | 2021-11-01 |
Showing 20 of 26. Sign in to see all of them.
Hepatitis (3) · Liver Diseases (3) · Acute-On-Chronic Liver Failure (2) · Alcoholism (2) · Fibrosis (2) · Liver Cirrhosis (2) · Liver Cirrhosis, Alcoholic (2) · Liver Diseases, Alcoholic (2) · Liver Failure (2) · Liver Failure, Acute (2) · Ascites (1) · Bacterial Infections (1) · Fatty Liver, Alcoholic (1) · Gastrointestinal Hemorrhage (1)
Alcohol-Induced Disorders (26) · Alcohol-Related Disorders (26) · Chemically-Induced Disorders (26) · Digestive System Diseases (26) · Substance-Related Disorders (26) · Liver Diseases, Alcoholic (24) · Hepatitis (23) · Liver Diseases (23) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Hepatic Insufficiency (5) · Fibrosis (3) · Liver Failure (3) · Infections (2) · Liver Cirrhosis (2)
Prednisolone (3) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (2) · Fecal Microbiota Transplantation (2) · Interleukin 1 Receptor Antagonist Protein (2) · Prednisone (2) · 25-hydroxycholesterol 3-sulfate (1) · ADX-629 (1) · Arginine (1) · Ascorbic Acid (1) · Drugs, Generic (1) · Filgrastim (1) · Glucose (1) · Granulocyte Colony-Stimulating Factor (1) · Injections (1) · Methylprednisolone (1)
Conatus Pharmaceuticals Inc. (2) · Durect (2) · Virginia Commonwealth University (2) · Aldeyra Therapeutics, Inc. (1) · Craig James McClain (1) · Gilead Sciences (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Imperial College London (1) · Indiana University (1) · Intercept Pharmaceuticals (1) · Loma Linda University (1) · Mack Mitchell (1) · Mayo Clinic (1) · MedRegen LLC (1) · Naga P. Chalasani (1)
United States (19) · United Kingdom (6) · France (3) · Austria (2) · Belgium (2) · Australia (1) · Canada (1) · Denmark (1) · South Korea (1) · Spain (1) · Switzerland (1)
Ali R Ahmadi, MD PhD (1) · Arthur J McCullough, MD (1) · Arun J Sanyal, MBBS MD (1) · Arun J Sanyal, MD (1) · Craig J McClain, M.D. (1) · Craig J McClain, MD (1) · David Hagerty, MD (1) · Gyongi Szabo, MD (1) · John A. Tayek, MD (1) · Mack C Mitchell, MD (1) · Mark Thursz (1) · Michel H Mendler, M.D. (1) · Naga Chalasani, MD (1) · Robert A Ashley (1)
PMID 37011138, PMID 11605686, PMID 15763232, PMID 21085006, PMID 23855300, PMID 25901427, PMID 31811953, PMID 34763711, PMID 35084335, PMID 35340032, PMID 36267499, PMID 37633275, PMID 38215876, PMID 38342441, PMID 39181422, PMID 39873544, PMID 39938959, PMID 40304564, PMID 41691535
U01AA021788 (2), U01AA021886 (2), U01AA021891 (2), 2016 (1), R21AA014269 (1), U01AA021840 (1), U01AA021883 (1), U01AA021893 (1), U01AA026934 (1), U01AA026966 (1)